Abstract: Methods and systems for tracking individual-based carbon offsets in real time using a distributed ledger are presented. One method includes: tracking, by a computing device having one or more processors, the movement of a user device associated with a user from a first location; receiving, via sensors on the user device, motion-specific data for a predetermined duration; creating feature vectors using the motion-specific data for the predetermined duration; applying a trained machine learning model to the feature vectors to determine a mode of transport for the movement; receiving by the computing device, an indication of the end of the movement at a second location; generating, based on the mode of transport, a carbon offset score; and recording, in a distributed ledger, a tokenized entry of the carbon offset score.

Abstract: A vibration damping device for a belt drive of an internal combustion engine includes a belt pulley, a hub and a decoupling device. The decoupling device connects the belt pulley and the hub to each other, and has at least two spring members. The spring members can be connected in series.

Abstract: A securing and centring device for securing fastening elements of a vibration damping device and for centring said vibration damping device on a component, such as a crankshaft. The securing and centring device may includes a securing mechanism that can be inserted into an opening of the vibration damping device and is configured to secure a fastening element inserted into the opening against falling out, a centering mechanism insertable into a further opening of the vibration damping device and into an assembly opening of said component for positioning and/or centering the vibration damping device and said component relative to each other, and a connecting member connecting the securing mechanism and the centering mechanism. A vibration damping device may include such a securing and centering device.

Abstract: A securing and centring device for securing fastening elements of a vibration damping device and for centring said vibration damping device on a component, such as a crankshaft. The securing and centring device may includes a securing mechanism that can be inserted into an opening of the vibration damping device and is configured to secure a fastening element inserted into the opening against falling out, a centering mechanism insertable into a further opening of the vibration damping device and into an assembly opening of said component for positioning and/or centering the vibration damping device and said component relative to each other, and a connecting member connecting the securing mechanism and the centering mechanism. A vibration damping device may include such a securing and centering device.

Abstract: A vibration damping device for a belt drive of an internal combustion engine includes a belt pulley, a hub and a decoupling device. The decoupling device connects the belt pulley and the hub to each other, and has at least two spring members. The spring members can be connected in series.

Abstract: A belt pulley having an integrated torsional oscillation damper. The torsional oscillation damper comprises a hub ring that encloses a flywheel ring. A radial first space is formed between the hub ring and the flywheel ring, wherein a first spring body is arranged in a first gap formed by the radial first space. A bushing is disposed between the hub ring and the flywheel ring to form a radial second space, wherein a second spring body is arranged in a second gap formed by the second radial space.

Abstract: A process for producing substantially optically pure sertraline utilizes chromatographic separation on a solid stationary chiral phase of spherical clay particles having an interlayer containing an optically pure metal-organic complex, and a liquid mobile phase preferably containing at least methyl acetate. The liquid mobile phase is preferably free of acetonitrile. The process is operable at temperatures above 40° C.

Abstract: A process for producing substantially optically pure sertraline utilizes chromatographic separation on a solid stationary chiral phase of spherical clay particles having an interlayer containing an optically pure metal-organic complex, and a liquid mobile phase preferably containing at least methyl acetate. The liquid mobile phase is preferably free of acetonitrile. The process is operable at temperatures above 40° C.

Abstract: The present invention provides a piperidine derivative of formula (I) ##STR1## in which R represents a straight- or branched-chain (C.sub.1 -C.sub.19)alkyl group, a straight- or branched-chain (C.sub.2 -C.sub.19)alkenyl group, a (C.sub.3 -C.sub.6)cycloalkyl group, a cycloalkylmethyl group in which the cycloalkyl moiety has from three to six carbon atoms, a phenyl group which is optionally substituted by a halogen atom or a phenyl methyl group which is optionally substituted by a halogen atom, or an addition salt thereof, in the form of an optically pure enantiomer or of a mixture of enantiomers, a process for making them and their therapeutic application.

Abstract: Pharmaceutical compositions which comprises a core comprising alfuzosin hydrochloride which core is coated with a coating whose dissolution is pH-dependent and applications to the preparation of sustained-release dosage compositions which are unable for a once-daily oral administration.

Abstract: A pharmaceutical preparation intended for transdermal administration contains alfusozin [(N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydr o-2-furancarboxamide] or a salt thereof and a mixture composed of water, at least one organic solvent and at least one absorption promoter.

Abstract: A process for the preparation of methyl (-)-(2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, which comprises subjecting the dextrorotatory (2S,3R) enantiomer, present in a starting mixture containing both the levorotatory (2R,3S and dextrorotatory (2S,3R) enantiomers, to a transesterification reaction, in an anhydrous medium and in the presence of an enzyme which does not affect the levorotatory (2R,3S) enantiomer. The latter is an intermediate for the synthesis of compounds such as Diltiazem.

Abstract: 2-Aminothiophenol is reacted with methyl (-)-(2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, and the intermediate methyl (2S,3S)-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionate is cyclized in the presence of methanesulfonic acid, in the same vessel and without isolating said intermediate product, using e.g. chlorobenzene as a solvent.

Abstract: Process for the preparation of compounds of the general formula (I) ##STR1## wherein R is hydrogen or (C.sub.1-4)alkyl.

Abstract: 2-Aminothiophenol is reacted with (-)-(2R,3S)-2,3-epoxy-3-(4-methoxyphenyl) methylpropionate, and the intermediate (2S,3S)-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl) methylpropionate is then cyclized in the presence of methane sulfonic acid, in the same container and without isolating said intermediate product, using chlorobenzene as a solvent.

Abstract: A process for the preparation of a methyl (+)-(2S,3S)-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionat e of the formula (I): ##STR1## in which X denotes hydrogen or chlorine, which process comprises reacting a 2-aminothiophenol of formula (II): ##STR2## in which X is as defined above, with methyl (-)-(2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, in a 1,2-dichloroethane solvent.

Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, hydroxyl, alkyoxy, benzyloxy, alkanoyloxy, or benzoyloxy, or when R.sub.2 is hydroxyl or methoxy in the 4-position and R.sub.3 is hydrogen, R.sub.1 may also represent hydroxymethyl carbamoyl or alkoxycarbonyl,R.sub.2 is hydrogen, halogen, alkyl, hydroxyl, or alkoxy,R.sub.3 is hydrogen or alkyl,R.sub.4 is alkyl (in which case the compounds are (.+-.)-erythro) or when R.sub.3 represents hydrogen, R.sub.4 may also be hydrogen, and R.sub.5 is hydrogen, halogen, alkyl, alkoxy, or three methoxy groups in the 3-, 4- and 5-positions and pharmaceutically acceptable acid addition salts thereof, with the exclusion of compounds wherein:(a) one of R.sub.1 and R.sub.2 is in the 4-position and is hydroxyl, alkoxy or benzyloxy, the other is in the 3-position and is hydrogen, hydroxyl, alkoxy or benzyloxy, and R.sub.3 and R.sub.5 are hydrogen and wherein:(b) R.sub.1 is in the 4-position and is halogen, R.sub.4 is methyl and R.sub.

Abstract: Diphenylazomethine derivatives of formula (I) ##STR1## wherein R.sub.1 is hydrogen or methyl and R.sub.2 is an --OH,--OM (M=alkaline metal or alkaline earth metal), --NH.sub.2 or --O(C.sub.1-4 alkyl) group, and which are in the form of cis or trans isomers or mixtures thereof, have central nervous system activity and can be used as antidepressants and anticonvulsants.

Abstract: Compounds of general formula (I) ##STR1## wherein R1 represents a phenyl, halophenyl, methylphenyl, ethylphenyl, methoxyphenyl, trifluoromethylphenyl or naphthyl group, R2 represents hydrogen or a methyl or phenyl group, and R3 represents hydrogen or a benzyl group, except compounds in which R1 is a phenyl or 4-fluorophenyl group, R2 is hydrogen and R3 is hydrogen or a benzyl group, and their pharmaceutically acceptable acid addition salts have useful anti-depressant and anti-ischaemic properties.

Abstract: 2-Aminothiophenol is reacted with methyl (-)-(2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate, and the intermediate methyl (2S,3S)-3-[(2-aminophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionate is cyclized in the presence of methanesulfonic acid, in the same vessel and without isolating said intermediate product, using e.g. chlorobenzene as a solvent.